Harmony Biosciences Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Harmony Biosciences Holdings has a total shareholder equity of $538.6M and total debt of $186.4M, which brings its debt-to-equity ratio to 34.6%. Its total assets and total liabilities are $858.4M and $319.8M respectively. Harmony Biosciences Holdings's EBIT is $178.1M making its interest coverage ratio 52.2. It has cash and short-term investments of $346.9M.
Key information
34.6%
Debt to equity ratio
US$186.42m
Debt
| Interest coverage ratio | 52.2x |
| Cash | US$346.91m |
| Equity | US$538.58m |
| Total liabilities | US$319.80m |
| Total assets | US$858.38m |
Recent financial health updates
Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15
These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Recent updates
Many Still Looking Away From Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Sep 25Harmony Biosciences: Advancing An Expanded Pipeline
Aug 15Harmony Biosciences Holdings (NASDAQ:HRMY) Has A Rock Solid Balance Sheet
Jul 15Investors Holding Back On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Jun 07Harmony Biosciences Holdings, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 03These 4 Measures Indicate That Harmony Biosciences Holdings (NASDAQ:HRMY) Is Using Debt Safely
Apr 04Market Cool On Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Earnings
Feb 09Fewer Investors Than Expected Jumping On Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)
Mar 21Does Harmony Biosciences Holdings (NASDAQ:HRMY) Deserve A Spot On Your Watchlist?
Dec 01Harmony Biosciences: In Harmony
Sep 23We Ran A Stock Scan For Earnings Growth And Harmony Biosciences Holdings (NASDAQ:HRMY) Passed With Ease
Aug 05Harmony Biosciences Non-GAAP EPS of $0.57 misses by $0.06, revenue of $107M beats by $6.25M
Aug 02Harmony Biosciences: Steady Revenue Generator Looking For A Future
May 26Harmony Biosciences: Strong Growth At A Reasonable Price
Mar 04Our First Look At Harmony Biosciences
Nov 04Financial Position Analysis
Short Term Liabilities: HRMY's short term assets ($458.3M) exceed its short term liabilities ($146.6M).
Long Term Liabilities: HRMY's short term assets ($458.3M) exceed its long term liabilities ($173.2M).
Debt to Equity History and Analysis
Debt Level: HRMY has more cash than its total debt.
Reducing Debt: HRMY's debt to equity ratio has reduced from 137.4% to 34.6% over the past 5 years.
Debt Coverage: HRMY's debt is well covered by operating cash flow (114.5%).
Interest Coverage: HRMY's interest payments on its debt are well covered by EBIT (52.2x coverage).